Columbia Researchers Pinpoint Endosome Dysfunction as the Earliest Driver of Alzheimer's Disease

Scientists have long understood the pathological hallmarks of Alzheimer's disease (搜索)搜索该疾病 in the brain, but the fundamental question of what initiates and drives the disease has remained elusive. Now, researchers at Columbia University's Alzheimer's Research Center are making groundbreaking strides in pinpointing where the disease begins and how it progresses, opening new avenues for therapeutic intervention.

Dr. Scott Small, director of Columbia's Alzheimer's Research Center, likens the challenge to a fire investigation. "Alzheimer's is a very slowly progressive disorder," Small said. "And by the time we typically get to see the brain, it's hard to really piece together and isolate the key source." The accumulated damage leaves behind so much cellular debris that identifying the original trigger has proven extraordinarily difficult.

The Endosome: Alzheimer's "Grand Central Station"

Small and his team have zeroed in on a specific cellular organelle as the primary culprit: the endosome. "This organelle is called the endosome. Think of the cell as a complex train track system and this is Grand Central Station, and that is the organelle defective first and foremost in Alzheimer's," Small explained.

Within the brain, tens of millions of cells function as tiny Grand Central Stations, with organelles moving in and out like trains, facilitating the processes that allow people to think, move, and feel emotions. In Alzheimer's patients, Small has identified what amounts to a defective train within this system. "When this breaks, the bubble bursts and the nano shuttle breaks down, you get complete traffic jams in Grand Central Station," he said.

From Mechanism to Therapeutic Development

Critically, the Columbia team is not stopping at identifying the mechanism—they are actively developing drugs to target it. When asked whether the defect can be fixed, Small responded affirmatively: "Not in human trials, but that's exactly what we're doing. We are developing drugs to fix that."

Dr. Yasir Qureshi, a colleague of Small, is advancing this work by studying both mouse models and postmortem brain tissue from Alzheimer's patients to analyze similar abnormalities across species. "We can design questions based on the mouse studies and then we can test them in those human brains, similar sections from similar areas that are representative," Qureshi said. "And if whatever we found in mice, does it translate to humans."

Rescuing Normal Cellular Function

The team has already demonstrated a critical proof of concept: the ability to reverse, or as Qureshi describes it, "rescue" normal cellular processes. "We were able to see that after expression, we were able to rescue this type of processes present in the normal self," Qureshi said. This finding has fueled confidence that what works in mice could ultimately work in people.

"The next steps are if this works, we'll do many more studies in academia first and then collaboration with industry to see if this can actually be developed into a drug," Qureshi added, outlining a clear translational roadmap from academic discovery to pharmaceutical development.

A Breakthrough on the Horizon

Taken together, the research has instilled strong conviction in the Columbia team that a meaningful therapeutic breakthrough is approaching. "The home run will be hit, I'm sure of it," Small said. "It may be two years, it may be five years but we're on the cusp."

The work represents a paradigm shift in Alzheimer's research—moving beyond the downstream pathology that has dominated the field toward targeting the earliest cellular defects that may initiate the entire disease cascade.